A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

NCT04074330 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Enrolment Challenges

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: TAK-981
DRUG: Rituximab

Sponsor

Takeda